MedPath

Genetics of Ventriculo-arterial Discordance

Not Applicable
Recruiting
Conditions
Heart Defects, Congenital
Registration Number
NCT05330338
Lead Sponsor
Nantes University Hospital
Brief Summary

Number of centres planned : 16 centres in France

Type of study / Study design : Research Involving the Human Person category 2.

Multicentric. Prospective

Planning of the study : Total duration: 22 years. Recruitment period: 24 months. Follow-up

time per patients : 20 years

Expected number of cases : The study will involve a maximum of 900 individuals, from 16 centers in France300 family trios (consisting of 150 index cases and their 2 parents, healthy volunteers, N= 450 individuals)

- In the event of unavailability, refusal, non-compliance with an inclusion or exclusion criterion concerning one of the biological parents, only the index case (patient) will be included in the study without his or her parents.

The 300 index cases with ventriculo-arterial discordance will be divided into two groups: 100 double discordance cases and 200 large-vessel transpositions.

These group inclusion targets are theoretical. If the proportion of patients available for inclusion turns out to be higher than expected for one of the groups, the targets may be adjusted, while maintaining a maximum of 300 cases included (corresponding to 900 subjects if all trios are complete).

Patients and their parents will be informed of the study by their referring cardiologist, and their written consent will be obtained.

Translated with DeepL.com (free version)

Treatment, procedure, combination of procedures under consideration :

* Blood samples for genetic analyses collected at the inclusion visit for patients and parents in case of trio families

Schedule of different visits and examinations :

Inclusion visit:

* Collection of demographic, clinical data from the index case and parents

* DNA sampling for genetic research (biocollection) of the index case or family trio

* Completion of the quality of life questionnaire

Annual visit with a 20 year follow-up:

* Retrieval of data from the index case

* Completion of the quality of life questionnaire

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Patients with transposition of the great arteries or transposition congenitally corrected of the great arteries with healthy parents and no family history of congenital heart disease (familial trio)
  • Or patients with transposition of the great arteries or transposition congenitally corrected of the great arteries with or without a history of congenital heart disease (familial form or sporadic case)
  • Affiliated or beneficiaries of a social security scheme or similar
  • After obtaining oral consent from patients and/or parents if applicable

Parents (for family trios) :

  • Biological parents of the child included in the PRECIPED study
Exclusion Criteria
  • Patients with transposition of the great arteries or transposition congenitally corrected of the great arteries with hypoplastic ventricle or atrioventricular and/or ventriculoarterial valve atresia
  • Patient with an identified malformation syndrome
  • Patients under guardianship/curatorship
  • Patients with State Medical Aid
  • Refusal of consent by the patient and/or one of the two parents

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Identification new genes/variants involved in congenital heart disease with transposition congenitally corrected of the great arteries, based on whole genome sequencing of familial trios.24 months

Identification of de novo genetic variants using a whole genome sequencing (WGS) approach in the context of familial trios analysis

Secondary Outcome Measures
NameTimeMethod
Identification new familial forms of ventriculo-arterial discordance.24 months

Identification of genotype/phenotype relationships by studying associations between clinical features and identified genetic variants.

Evaluation the diagnostic contribution of parental cardiovascular screening in case of ventriculo-arterial discordance (transposition of the great arteries, transposition congenitally corrected of the great arteries) in the index case.24 months

Evolution of diagnostic performance for congenital heart disease in relatives of the index case with ventriculo-arterial discordance following the introduction of parental screening.

Identification allelic variants associated with prognosis and/or response to treatment, with the aim of eventually developing a precision medicine programme in paediatric cardiology20 years

Identification of genotype/phenotype relationships in relation to prognosis and/or response to treatment

Identification epigenetic modifications by analysis of the epigenome of sporadic forms when genome sequencing is not contributory.24 months

Detection of epigenetic modifications.

Assessing the quality of life of patients with ventriculo-arterial discordance as well as their parents20 years

To document quality of life longitudinally in this patient population using The Short Form (36) Health Survey (scale from 1 to 6 ; 6 being the worst outcome)

Trial Locations

Locations (16)

CHU Marseille

馃嚝馃嚪

Marseille, Bouches-du-Rh么ne, France

CHU Rennes

馃嚝馃嚪

Rennes, Bretagne, France

CHU Bordeaux

馃嚝馃嚪

Bordeaux, Gironde, France

CHU Toulouse

馃嚝馃嚪

Toulouse, Haute-Garonne, France

CHU de Lille

馃嚝馃嚪

Lille, Hauts-de-France, France

CHU Nancy

馃嚝馃嚪

Nancy, Meurthe-et-Moselle, France

Groupe Hospitalier St Joseph - H么pital Marie Lannelongue

馃嚝馃嚪

Le Plessis-Robinson, Hauts-de-Seine, France

CHU Nantes

馃嚝馃嚪

Nantes, Loire-Atlantique, France

H么pital Nord Laennec

馃嚝馃嚪

Saint-Herblain, Loire-Atlantique, France

CHU Angers

馃嚝馃嚪

Angers, Maine-et-Loire, France

Intercard Lille

馃嚝馃嚪

Lille, Nord, France

CHU de Caen

馃嚝馃嚪

Caen, Normandie, France

CHU Lyon

馃嚝馃嚪

Lyon, Rh么ne, France

CHU Rouen

馃嚝馃嚪

Rouen, Seine-Maritime, France

CHU Tours

馃嚝馃嚪

Tours, Val de Loire, France

H么pital Europ茅en Georges Pompidou

馃嚝馃嚪

Paris, France

漏 Copyright 2025. All Rights Reserved by MedPath